NCT02579993

Brief Summary

In this study the prognostic value of ABCB5 in survival of the limbal stem cell transplantation expanded in vitro on amniotic membrane for corneal surface reconstruction in patients with limbal stem cell deficiency will be analyzed.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 11, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 20, 2015

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

March 6, 2018

Status Verified

March 1, 2018

Enrollment Period

3 years

First QC Date

October 11, 2015

Last Update Submit

March 5, 2018

Conditions

Keywords

CorneaLimbal stem cell

Outcome Measures

Primary Outcomes (2)

  • Objective clinical evaluation

    A grading system from 0 to 4 using photographs taken with slit lamp, will be used to determine by two independent examiners the degree of corneal transparency and superficial vascularization.

    6 months

  • Objective clinical evaluation

    A grading system from 0 to 4 using photographs taken with slit lamp, will be used to determine by two independent examiners the degree of corneal transparency and superficial vascularization.

    12 months

Secondary Outcomes (6)

  • Corneal cells morphology

    6 months

  • Corneal cells morphology

    12 months

  • Quality of life questionnaire

    6 months

  • Quality of life questionnaire

    12 months

  • Visual acuity

    6 months

  • +1 more secondary outcomes

Study Arms (1)

Stem Cell Transplantation

EXPERIMENTAL

Cultivated Limbal Stem Cell Transplantation

Procedure: Pannus and conjunctival dissectionProcedure: Human cultivated limbal stem cell transplantation

Interventions

A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.

Stem Cell Transplantation

The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.

Stem Cell Transplantation

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Bilateral limbal stem cell deficiency of any etiology.
  • Corneal impression cytology positive for goblet cells.
  • Ocular ultrasound results within normal parameters.
  • Agree to participate in the study and sign the informed consent.

You may not qualify if:

  • \. Active immunological diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto de Oftalmologia Conde de Valenciana

Mexico City, 06800, Mexico

Location

Related Publications (1)

  • Serna-Ojeda JC, Garcia-Mejia M, Graue-Hernandez EO, Navas A, Garfias Y. Short-Term Results Analysis in the Allogenic Transplantation of Limbal Stem Cells Expanded on Amniotic Membrane in Patients with Bilateral Limbal Stem Cell Deficiency. J Ocul Pharmacol Ther. 2020 May;36(4):238-246. doi: 10.1089/jop.2019.0147. Epub 2020 Feb 20.

MeSH Terms

Conditions

Limbal Stem Cell DeficiencyCorneal Diseases

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Yonathan Garfias, MD, PhD

    Instituto de Oftalmologia Conde de Valenciana

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 11, 2015

First Posted

October 20, 2015

Study Start

March 1, 2015

Primary Completion

March 1, 2018

Study Completion

March 1, 2018

Last Updated

March 6, 2018

Record last verified: 2018-03

Locations